Company profile

Theratechnologies

Privately held: no public share price (Acquired by a Future Pak (CB Biotechnology, LLC) affiliate, delisted from Nasdaq/TSX and deregistered, completed 2025-09-25.)

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Ibalizumab(Trogarzo)
Approved
CD4 receptorMonoclonal antibody
HIV
Tesamorelin(Egrifta WR)
Approved
Growth hormone-releasing hormone (GHRH) receptorPeptide
HIV

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.